NEW YORK--(BUSINESS WIRE)--The Klein Law Firm announces the commencement of an investigation of Celgene Corporation (NASDAQGS:CELG) concerning possible violations of federal securities laws.
Celgene announced it would discontinue its trials for GED-0301 on October 19, 2017. The Company also announced it would record a $1.6 billion impairment charge because of the drug’s failure. On October 26, 2017, Celgene identified some of its key drugs that had missed sales expectations for the quarter. Then on February 27, 2018, post-market, Celgene disclosed that the U.S. Food and Drug Administration (“FDA”) had rejected the Company’s New Drug Application (“NDA”) for Ozanimod, a multiple sclerosis treatment. Celgene stated that it had received a refusal-to-file letter from the FDA, which advised the Company that it had “determined that the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review.”
If you suffered a loss in Celgene and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/CELG-Info-Request-Form-285.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665